Journal of International Psychiatry

[Abstract] Objective To explore the effect of Ai Sciplan and citalopram on the improvement of anxiety in patients with recurrent glioma. Methods A total of 82 patients with recurrent glioma anxiety admitted to our hospital from July 2007 to February 2018 were randomly divided into observation group and control group, with 41 cases in each group. The control group was treated with citalopram after operation. The observation group received oral escitalopram oxalate tablets. The two groups were given orally for 8 weeks. The total effective rate, the degree of anxiety before and after 8 weeks of treatment [assessed by the Hamilton Anxiety Scale (HAMA)], the total incidence of adverse reactions were compared between the two groups. Results The total effective rate of the observation group was 70.73%, which was higher than 48.78% of the control group, the difference was statistically significant (P<0.05). There was no significant difference in the HAMA scores between the two groups before treatment (P>0.05). After 8 weeks of treatment, the HAMA scores of the two groups were significantly lower than those before treatment (P<0.05). The HAMA score of the observation group after 8 weeks of treatment was (9.79±1.99) points, which was lower than that of the control group (13.22±2.34), and the difference was statistically significant (P<0.05). The total incidence of adverse reactions in the observation group and the control group were 17.07% and 12.20%, the difference was not statistically significant (P>0.05). Conclusion The escitalopram has a stronger inhibitory effect on 5-HT reuptake, and it is superior to citalopram in improving the symptoms of recurrent glioma anxiety patients, and it is safe and is an ideal therapeutic drug for such patients.

[Key words] Recurrent glioma anxiety; Postoperative anxiety; Escitalopram; Citalopram